Per Sandström

5.3k total citations
17 papers, 215 citations indexed

About

Per Sandström is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Per Sandström has authored 17 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Per Sandström's work include Radiopharmaceutical Chemistry and Applications (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Renal cell carcinoma treatment (5 papers). Per Sandström is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Renal cell carcinoma treatment (5 papers). Per Sandström collaborates with scholars based in Sweden, United States and Germany. Per Sandström's co-authors include Ulrika Harmenberg, Maria Jakobsson, Jan Kowalski, Börje Ljungberg, Sven Lundstam, Rickard Sandin, Anders Ullén, John Lövrot, Arne Östman and Artur Mezheyeuski and has published in prestigious journals such as Cancer, British Journal of Cancer and Medicine.

In The Last Decade

Per Sandström

17 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Per Sandström Sweden 7 150 87 78 51 47 17 215
Barbara L. Pruetz United States 10 78 0.5× 94 1.1× 70 0.9× 35 0.7× 54 1.1× 22 249
M. Gross Goupil France 9 164 1.1× 98 1.1× 70 0.9× 20 0.4× 63 1.3× 26 213
Carlos Mayo United States 9 151 1.0× 75 0.9× 164 2.1× 14 0.3× 41 0.9× 16 254
Elizabeth Liow Australia 10 116 0.8× 66 0.8× 131 1.7× 16 0.3× 46 1.0× 26 235
Maddalena Donini Italy 8 112 0.7× 69 0.8× 64 0.8× 11 0.2× 49 1.0× 29 191
Simon Fu New Zealand 6 176 1.2× 62 0.7× 96 1.2× 16 0.3× 99 2.1× 11 205
Matthew Labriola United States 6 159 1.1× 72 0.8× 137 1.8× 14 0.3× 82 1.7× 23 238
J.D. Forman United States 9 274 1.8× 52 0.6× 102 1.3× 33 0.6× 74 1.6× 23 358
M. Dómine Gómez Spain 9 128 0.9× 73 0.8× 210 2.7× 25 0.5× 22 0.5× 36 277
L Morrissey United States 3 130 0.9× 121 1.4× 113 1.4× 8 0.2× 49 1.0× 4 248

Countries citing papers authored by Per Sandström

Since Specialization
Citations

This map shows the geographic impact of Per Sandström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Sandström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Sandström more than expected).

Fields of papers citing papers by Per Sandström

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Sandström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Sandström. The network helps show where Per Sandström may publish in the future.

Co-authorship network of co-authors of Per Sandström

This figure shows the co-authorship network connecting the top 25 collaborators of Per Sandström. A scholar is included among the top collaborators of Per Sandström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Sandström. Per Sandström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
García‐Albéniz, Xabier, Pär Stattin, Marcus Westerberg, et al.. (2023). Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiology and Drug Safety. 32(7). 812–815. 2 indexed citations
2.
Viktorsson, Kristina, Petra Hååg, Bo Franzén, et al.. (2022). Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. Molecular Oncology. 16(20). 3620–3641. 6 indexed citations
3.
Stattin, Pär, Marcus Westerberg, Ingela Franck Lissbrant, et al.. (2022). Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden. Clinical Genitourinary Cancer. 21(1). 107.e1–107.e9. 11 indexed citations
4.
Sjöberg, Elin, John Lövrot, Artur Mezheyeuski, et al.. (2018). A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. British Journal of Cancer. 119(7). 840–846. 44 indexed citations
5.
Staehler, Michael, Bernadett Szabados, Per Sandström, et al.. (2018). Metastatic papillary renal cell carcinoma in the era of targeted therapy – a retrospective study from three European academic centres. Acta Oncologica. 58(3). 306–312. 3 indexed citations
6.
Farnebo, Jacob, et al.. (2017). Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study. European Journal of Radiology Open. 4. 45–49. 1 indexed citations
7.
Farnebo, Jacob, Per Sandström, Sten Nilsson, et al.. (2016). Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT. Medicine. 95(31). e4308–e4308. 4 indexed citations
8.
Nearchou, Andreas, Antonis Valachis, Pehr Lind, Olof Akre, & Per Sandström. (2014). Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. Clinical Genitourinary Cancer. 13(4). 280–286. 17 indexed citations
9.
Farnebo, Jacob, Per Grybäck, Ulrika Harmenberg, et al.. (2014). Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer. 14(1). 408–408. 25 indexed citations
10.
Harmenberg, Ulrika, Per Sandström, Sven Lundstam, et al.. (2013). Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). British Journal of Cancer. 108(7). 1541–1549. 79 indexed citations
11.
Viktorsson, Kristina, Amir Sherif, Lena Kanter, et al.. (2013). Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient. Anti-Cancer Drugs. 24(6). 648–652. 1 indexed citations
12.
Sandström, Per, et al.. (1999). Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting.. PubMed. 5(10 Suppl). 3073s–3078s. 5 indexed citations
13.
14.
Stigbrand, Torgny, Anders Ullén, Per Sandström, et al.. (1997). Endogenous anti-tumor antibody responses in nude mice. Cancer. 80(S12). 2404–2410. 2 indexed citations
15.
Ullén, Anders, et al.. (1997). Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies. Cancer. 80(S12). 2681–2688. 6 indexed citations
16.
Stigbrand, Torgny, Anders Ullén, Per Sandström, et al.. (1997). Endogenous anti‐tumor antibody responses in nude mice. Cancer. 80(S12). 2404–2410. 2 indexed citations
17.
Ullén, Anders, Per Sandström, Katrine Riklund, et al.. (1995). Use of anticytokeratin monoclonal antiidiotypic antibodies to improve tumor / non tumor ratio at experimental radioimmunolocalisation. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara L. Pruetz Breakdown of academic impact, for papers by M. Gross Goupil Breakdown of academic impact, for papers by Carlos Mayo Breakdown of academic impact, for papers by Elizabeth Liow Breakdown of academic impact, for papers by Maddalena Donini Breakdown of academic impact, for papers by Simon Fu Breakdown of academic impact, for papers by Matthew Labriola Breakdown of academic impact, for papers by J.D. Forman Breakdown of academic impact, for papers by M. Dómine Gómez Breakdown of academic impact, for papers by L Morrissey
Rankless by CCL
2026